Frontier Medicines

I know I’m not alone in saying that this was an inspiring ASCO for the #oncology community. Across multiple tumor types, we saw compelling examples of how advances in biology, drug discovery, and clinical development are translating into meaningful progress for patients. For those of us who have spent years focused on RAS biology, the data presented this year felt particularly significant. Seeing daraxonrasib demonstrate a substantial survival benefit in previously treated metastatic pancreatic cancer was a powerful reminder of how far the field has come. For a disease where meaningful therapeutic progress has been difficult to achieve, these results represent an important milestone and further validate the potential of innovative approaches to targeting RAS-driven cancers. As a co-founder of Warp Drive Bio, which developed the chemistry and assets that Revolution Medicines progressed via a merger, and having played a small part in the advancement of daraxonrasib, this achievement is particularly meaningful, humbling and inspiring for me. What stands out is not only the progress itself, but what it signals for the future. These breakthroughs are the product of decades of scientific commitment, challenging long-held assumptions, and a willingness to pursue difficult problems that many once considered out of reach. These are exactly the kinds of advances that inspire us to continue pushing the boundaries of science in pursuit of better treatments for patients. By harnessing #AI to deepen our understanding of complex biology, we believe there is an extraordinary opportunity to accelerate discovery and expand what is possible for patients. Read more here about the impact of daraxonrasib: https://lnkd.in/eTZQ6bvc

Only 7% of the druggable proteome has been pharmacologically explored. That's not just a scientific gap. It's a data gap and it limits what AI can do for patients. Our co-founder and CEO Chris Varma breaks down the data challenges constraining AI in small molecule #drugdiscovery in the latest edition of Drug Discovery and Development, including: - Missing data: Negative results go unpublished, leaving #AI models systematically biased toward false positives - Poor quality data: With reproducibility rates as low as 11% in landmark cancer studies, AI learns the wrong lessons - Unstructured data: Over 80% of life sciences data isn't compute-ready, which slows model training and performance Read Chris' full perspective on what it will take to truly unleash AI for drug discovery at the link below. ⬇️ https://lnkd.in/dQyYpGHs

Don't forget to check out our poster presentations at #AACR26 tomorrow! More info below. ⬇️

This weekend, we are headed to the West Coast for the American Association for Cancer Research Annual Meeting in San Diego! We look forward to seeing you there. Be sure to stop by on Tuesday, April 21 for our two poster sessions. We will be sharing sharing preclinical findings on  FMC-242, a novel targeted therapy developed to address cancers driven by RAS and PI3Ka alterations, as well as how our Frontier™ Platform leverages CovalentAI™ and large-scale chemoproteomics to unlock historically undruggable #cancer targets. #AACR26

Our chief technology officer, Johannes Hermann, will speak at the Drug Discovery Chemistry Conference on April 16. Johannes will discuss how Frontier’s platform is helping unlock high-value, traditionally hard-to-drug targets by integrating chemoproteomics, covalent chemistry and #AI-driven insights. If you’re attending #DrugDiscoveryChemistry 2026, we encourage you to join the session. Learn more about the event here: https://lnkd.in/dgndFQT

We’re excited to welcome David Epstein to our board of directors. David is a proven biopharma leader with a track record of scaling companies, delivering breakthrough medicines and driving transformational growth, helping to bring more than 30 new medicines to market in his tenured career. His appointment comes at a pivotal time as we advance a pipeline of potentially best-in-class precision medicines and continue to expand the reach of the Frontier™ Platform. With leaders like David joining our team, we’re well positioned to accelerate execution, unlock new opportunities and deliver meaningful impact for patients. Read more: https://lnkd.in/eJ32C2BR

Our chief innovation officer Daniel Erlanson and executive director, protein sciences and structural biology Weiru Wang were recently featured in Drug Discovery World, highlighting how chemoproteomics and covalent approaches are opening new possibilities for targeting E3 ligases. In the article, they explore how these technologies can help unlock previously inaccessible targets and expand what’s possible for next-generation therapeutics. Read the full piece here: https://lnkd.in/e_PR-H4q

We're excited to share we have granted an exclusive worldwide license to LG Chem to develop and commercialize FMC-220 outside of Greater China, with Frontier retaining ownership and full control in Greater China. FMC-220 is a first-in-class covalent p53 Y220C activator being evaluated for the treatment of solid tumor cancers with TP53 loss-of-function mutations. This partnership underscores the value of our Frontier™ Platform and our ability to generate high-impact programs against challenging targets, creating meaningful opportunities for long-term value through milestones and royalties. Read more in the full press release: https://lnkd.in/e5kyjyW2

We’re looking forward to the upcoming AACR Annual Meeting 2026 in San Diego. Our team will present preclinical findings on FMC-242, a novel targeted therapy developed to address cancers driven by RAS and PI3Ka alterations. In preclinical models, FMC-242 demonstrated robust anti-tumor activity both as a monotherapy and in combination with other targeted therapies.  We will also present how our Frontier™ Platform leverages covalent #AI and large-scale chemoproteomics to unlock historically undruggable cancer targets, with covalent fragment hits identified for over 75% of key cancer driver genes and an autonomous AI-driven drug design engine accelerating the path to novel covalent medicines. For more on the posters and timing, check out our release below. ⬇️  We hope to see you at #AACR26! https://lnkd.in/e2j2F6Wy

The Frontier team is on the road again. This week, members of our team are at the Leerink Global Healthcare Conference down in Miami. We're excited to engage with other industry leaders and share more about the innovative work we are doing at Frontier.